Platelet glycoprotein ib alpha fusion polypeptides and methods of use thereof

Abstract

The present invention provides compositions and methods for treating or preventing vascular-associated disorders.

1 - 53 . (canceled) 
     
     
         54 . A method for treating a disorder associated with platelet activation in a subject, the method comprising administering to a subject in need thereof a polypeptide comprising the amino acid sequence of SEQ ID NO:5. 
     
     
         55 . A method for treating venous or coronary artery thrombosis in a subject in need thereof comprising administering to the subject a polypeptide comprising the amino acid sequence of SEQ ID NO:5. 
     
     
         56 . The method of  claim 54 , wherein the disorder is selected from the group consisting of restenosis, ischemic heart disease, angina, unstable angina, atherosclerosis, acute myocardial infarction, or vascular inflammation. 
     
     
         57 . The method of  claim 56 , wherein the disorder is restenosis. 
     
     
         58 . The method of  claim 56 , wherein the disorder is angina. 
     
     
         59 . The method of  claim 58 , wherein the disorder is unstable angina. 
     
     
         60 . The method of  claim 56 , wherein the disorder is ischemic heart disease. 
     
     
         61 . The method of  claim 56 , wherein the disorder is atherosclerosis. 
     
     
         62 . The method of  claim 56 , wherein the disorder is acute myocardial infarction. 
     
     
         63 . The method of  claim 56 , wherein the disorder is vascular inflammation. 
     
     
         64 . The method of  claim 54 , wherein the method further comprises administering a compound selected from the group consisting of acetylsalicylic acid, heparin, and clopidogrel. 
     
     
         65 . The method of  claim 55 , wherein the method further comprises administering a compound selected from the group consisting of acetylsalicylic acid, heparin, and clopidogrel. 
     
     
         66 . The method of  claim 54 , wherein the method further comprises administering a glycoprotein IIb/IIIa antagonist, a P-selectin antagonist, a thrombin inhibitor, or a thrombolytic enzyme. 
     
     
         67 . The method of  claim 55 , wherein the method further comprises administering a glycoprotein IIb/IIIa antagonist, a P-selectin antagonist, a thrombin inhibitor, or a thrombolytic enzyme. 
     
     
         68 . The method of  claim 54 , wherein the subject is a mammal. 
     
     
         69 . The method of  claim 55 , wherein the subject is a mammal. 
     
     
         70 . The method of  claim 54 , wherein the subject is human. 
     
     
         71 . The method of  claim 55 , wherein the subject is human. 
     
     
         72 . The method of  claim 54 , wherein the polypeptide is a dimer. 
     
     
         73 . The method of  claim 55 , wherein the polypeptide is a dimer.